Thyroid nodule
Conditions
Interventions
remimazolam:remimazolam 1~3mg/kg/h
Propofol:Propofol TCI 2~4ug/ml
Sponsors
Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18- 65 years, American Society of Anaesthesiologists (ASA) physical status classification I-III. 2. Patients undergoing thyroid surgery require IONM. 3. Expected duration of surgery to be 4 hours or less. 4. Body mass index (BMI) >= 18 kg/m2 and <= 30 kg/m2. 5. Participation in the study is voluntary and requires signed informed consent.
Exclusion criteria
Exclusion criteria: 1.Participated in other clinical trials within the past 3 months. 2.Patients undergoing other surgery at the same time, emergency surgery, and subsequent admission to intensive care for post-operative care. 3.Patients with suspected allergy to remimazolam, propofol or any of the drugs used in this study (e.g. sufentanil, rocuronium, remifentanil, ciprofol, etc.). 4.Severe systemic cardiovascular disease, such as congestive heart failure, frequent premature ventricular contractions, uncontrolled hypertension/hypotension, etc. 5.Severe respiratory disease. 6.History of dementia, mental illness, or other central nervous system disorders, and current use of sedatives, or antidepressants. 7.End-stage liver failure or kidney disease requiring dialysis. 8.Researcher does not believe it is appropriate to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the occurrence of hypotension, defined as MAP= 30% below preoperative baseline, from induction of anesthesia to full recovery.; | — |
Secondary
| Measure | Time frame |
|---|---|
| the administration of vasoactive agents; the number of hypotension or hypertension episodes requiring intervention;the cumulative duration of hypotension or hypertension;the dose of intraoperative rescue sedation and analgesia;the duration of extubation and awakening;the incidence of adverse events; | — |
Countries
China
Contacts
Public ContactYao Yonghua
Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University
Outcome results
None listed